VITRAKVI 20 mg/mL
LAROTRECTINIB · SOLUTION · Loxo Oncology, Inc.
VITRAKVI is a solution containing larotrectinib at 20 mg/mL, taken oral. Manufactured by Loxo Oncology, Inc..
Key Facts
- Brand Name
- VITRAKVI
- Generic Name
- LAROTRECTINIB
- NDC Code (Product)
71777-392- Manufacturer
- Loxo Oncology, Inc.
- Strength
- 20 mg/mL
- Dosage Form
- SOLUTION
- Route
- ORAL
- Marketing Status
- Application #
- NDA211710
- Drug Class
- Kinase Inhibitor [EPC]
- Marketing Start
- 11/26/2018
Recall History
Bayer Healthcare Pharmaceuticals Inc.
Microbial Contamination of Non-Sterile Products: microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing
Frequently Asked Questions
What is VITRAKVI used for?
VITRAKVI contains LAROTRECTINIB. It is a solution taken oral. Consult your doctor for specific uses.
Is VITRAKVI a controlled substance?
VITRAKVI is not classified as a controlled substance by the DEA.
What is the generic name for VITRAKVI?
The generic name for VITRAKVI is LAROTRECTINIB. There are no other listed brand versions of LAROTRECTINIB.
What is the NDC code for VITRAKVI 20 mg/mL?
The NDC (National Drug Code) for VITRAKVI 20 mg/mL is 71777-392, listed by Loxo Oncology, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)